These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

476 related articles for article (PubMed ID: 38518167)

  • 21. A novel focal adhesion-related risk model predicts prognosis of bladder cancer -- a bioinformatic study based on TCGA and GEO database.
    Hu J; Wang L; Li L; Wang Y; Bi J
    BMC Cancer; 2022 Nov; 22(1):1158. PubMed ID: 36357874
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
    Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
    Front Genet; 2022; 13():919389. PubMed ID: 35783281
    [No Abstract]   [Full Text] [Related]  

  • 23. Integrating single-cell RNA-seq to identify fibroblast-based molecular subtypes for predicting prognosis and therapeutic response in bladder cancer.
    Wang J; Tan Z; Huang Y; Li C; Zhan P; Wang H; Li H
    Aging (Albany NY); 2024 Jul; 16(14):11385-11408. PubMed ID: 39033778
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor Expression Profile Analysis Developed and Validated a Prognostic Model Based on Immune-Related Genes in Bladder Cancer.
    Dong B; Liang J; Li D; Song W; Zhao S; Ma Y; Song J; Zhu M; Yang T
    Front Genet; 2021; 12():696912. PubMed ID: 34512722
    [No Abstract]   [Full Text] [Related]  

  • 25. A sialyltransferases-related gene signature serves as a potential predictor of prognosis and therapeutic response for bladder cancer.
    Cao P; Chen M; Zhang T; Zheng Q; Liu M
    Eur J Med Res; 2023 Nov; 28(1):515. PubMed ID: 37968767
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Crosstalk of disulfidptosis-related subtypes, establishment of a prognostic signature and immune infiltration characteristics in bladder cancer based on a machine learning survival framework.
    Zhao S; Wang L; Ding W; Ye B; Cheng C; Shao J; Liu J; Zhou H
    Front Endocrinol (Lausanne); 2023; 14():1180404. PubMed ID: 37152941
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A robust signature of immune-related long non-coding RNA to predict the prognosis of bladder cancer.
    Lai C; Wu Z; Li Z; Yu H; Li K; Tang Z; Liu C; Xu K
    Cancer Med; 2021 Sep; 10(18):6534-6545. PubMed ID: 34374227
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comprehensive analysis of immune-related gene signature based on ssGSEA algorithms in the prognosis and immune landscape of hepatocellular carcinoma.
    Wang L; Wang L; He P
    Front Genet; 2022; 13():1064432. PubMed ID: 36568383
    [No Abstract]   [Full Text] [Related]  

  • 29. Identification of immune-related LncRNA for predicting prognosis and immunotherapeutic response in bladder cancer.
    Wu Y; Zhang L; He S; Guan B; He A; Yang K; Gong Y; Li X; Zhou L
    Aging (Albany NY); 2020 Nov; 12(22):23306-23325. PubMed ID: 33221763
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A Novel TGF-β Risk Score Predicts the Clinical Outcomes and Tumour Microenvironment Phenotypes in Bladder Cancer.
    Liu Z; Qi T; Li X; Yao Y; Othmane B; Chen J; Zu X; Ou Z; Hu J
    Front Immunol; 2021; 12():791924. PubMed ID: 34975891
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Comprehensive analysis of scRNA-Seq and bulk RNA-Seq reveals dynamic changes in the tumor immune microenvironment of bladder cancer and establishes a prognostic model.
    Tan Z; Chen X; Zuo J; Fu S; Wang H; Wang J
    J Transl Med; 2023 Mar; 21(1):223. PubMed ID: 36973787
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Development and validation of a novel liquid-liquid phase separation gene signature for bladder cancer.
    Guo S; Su Q; Yang Z; Mo W
    Sci Rep; 2024 Sep; 14(1):22552. PubMed ID: 39343809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A novel immune checkpoint-related seven-gene signature for predicting prognosis and immunotherapy response in melanoma.
    Tian M; Yang J; Han J; He J; Liao W
    Int Immunopharmacol; 2020 Oct; 87():106821. PubMed ID: 32731180
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A novel CD8
    Lin F; Ke ZB; Xue YT; Chen JY; Cai H; Lin YZ; Li XD; Wei Y; Xue XY; Xu N
    Inflamm Res; 2023 Aug; 72(8):1665-1687. PubMed ID: 37578544
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Anoikis-related lncRNA signature predicts prognosis and is associated with immune infiltration in hepatocellular carcinoma.
    Zhu J; Zhao W; Yang J; Liu C; Wang Y; Zhao H
    Anticancer Drugs; 2024 Jun; 35(5):466-480. PubMed ID: 38507233
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Disulfidptosis characterizes the tumor microenvironment and predicts immunotherapy sensitivity and prognosis in bladder cancer.
    Pan G; Xie H; Xia Y
    Heliyon; 2024 Feb; 10(3):e25573. PubMed ID: 38356551
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of an Autophagy-Immune Related Genes Score Signature and Prognostic Model and its Correlation with Immune Response for Bladder Cancer.
    Yu J; Mao W; Sun S; Hu Q; Wang C; Xu Z; Liu R; Chen S; Xu B; Chen M
    Cancer Manag Res; 2022; 14():67-88. PubMed ID: 35023971
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Predictive role of ferroptosis-related long non-coding RNAs in bladder cancer and their association with immune microenvironment and immunotherapy response.
    Liu J; Zhang Z; Liu X; Zhang W; Meng L; Wang J; Lv Z; Xia H; Zhang Y; Wang J
    World J Surg Oncol; 2022 Feb; 20(1):47. PubMed ID: 35209909
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Results from a real-world study: a novel glycosyltransferase risk score for prognosis, tumor microenvironment phenotypes and immunotherapy in bladder cancer.
    Liu R; Yang T; Huang J; Xiao Z; Liu J; Li Z; Tong S
    BMC Cancer; 2024 Aug; 24(1):947. PubMed ID: 39095785
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Novel Natural Killer Cell-related Gene Signature for Improving the Prediction of Prognosis and Immunotherapy Response in Bladder Cancer.
    Ma X; Wei X; Yang G; Li S; Liu R
    Comb Chem High Throughput Screen; 2024; 27(8):1205-1221. PubMed ID: 37653625
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.